CSCarlos Sialer

Carlos Sialer

*This is an algorithmically generated author record based on publicly available information.

Carlos Sialer has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Alfredo F. Braña

    Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain

    2 shared publications
  • Carmen Méndez

    Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain

    2 shared publications
  • Jose A. Salas

    Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias (I.U.O.P.A), Universidad de Oviedo, 33006 Oviedo, Spain

    2 shared publications
  • Adriana Albini

    Scientific Directorate, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 20141 Milan, Italy

    1 shared publication
  • Antonino Bruno

    Laboratory of Immunology and General Pathology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy

    1 shared publication
  • Carlos Olano

    Functional Biology Department, University of Oviedo, 33006 Oviedo, Spain

    1 shared publication

Latest Publications

  • Open Access

    Evaluation of commercial doses of a feed additive and silymarin on broiler performance with and without CCl4-induced liver damage

    by Mabel Barreiro Carpio, M. Alejandro Valdes-Pena, Daniel A. Molina, Sandra E.J. Espinoza Cabello, Carlos A. Sialer Guerrero, Giovanna Cribillero, Katherine F. Vargas Coca, Eliana Icochea


  • Open Access

    Searching for Glycosylated Natural Products in Actinomycetes and Identification of Novel Macrolactams and Angucyclines

    by Mónica G. Malmierca, Lorena González-Montes, Ignacio Pérez-Victoria, Carlos Sialer, Alfredo F. Braña, Raúl García Salcedo, Jesús Martín, Fernando Reyes, Carmen Méndez, Carlos Olano, et al.

    Many bioactive natural products are glycosylated compounds in which the sugar components usually participate in interaction and molecular recognition of the cellular target. Therefore, the presence of sugar moieties is important, in some cases essential, for bioactivity. Searching for novel glycosylated bioactive compounds is an important aim in the field of the research for natural products from actinomycetes. A great majority of these sugar moieties belong to the 6-deoxyhexoses and share two common biosynthetic steps catalyzed by a NDP-D-glucose synthase (GS) and a NDP-D-glucose 4,6-dehydratase (DH). Based on this fact, seventy one Streptomyces strains isolated from the integument of ants of the Tribe Attini were screened for the presence of biosynthetic gene clusters (BGCs) for glycosylated compounds. Total DNAs were analyzed by PCR amplification using oligo primers for GSs and DHs and also for a NDP-D-glucose-2,3-dehydratases. Amplicons were used in gene disruption experiments to generate non-producing mutants in the corresponding clusters. Eleven mutants were obtained and comparative dereplication analyses between the wild type strains and the corresponding mutants allowed in some cases the identification of the compound coded by the corresponding cluster (lobophorins, vicenistatin, chromomycins and benzanthrins) and that of two novel macrolactams (sipanmycin A and B). Several strains did not show UPLC differential peaks between the wild type strain and mutant profiles. However, after genome sequencing of these strains, the activation of the expression of two clusters was achieved by using nutritional and genetic approaches leading to the identification of compounds of the cervimycins family and two novel members of the warkmycins family. Our work defines a useful strategy for the identification new glycosylated compounds by a combination of genome mining, gene inactivation experiments and the activation of silent biosynthetic clusters in Streptomyces strains.


  • SANIST: optimization of a technology for compound identification based on the European Union directive with applications in forensic, pharmaceutical and food analyses

    by Simone Cristoni, Guglielmo Dusi, Paolo Brambilla, Adriana Albini, Matteo Conti, Maura Brambilla, Antonino Bruno, Francesca Di Gaudio, Luca Ferlin, Valeria Tazzari, et al.

    Electrospray Ionization and collision induced dissociation tandem mass spectrometry are usually employed to obtain compound identification through a mass spectra match. Different algorithms have been developed for this purpose (for example the nist match algorithm). These approaches compare the tandem mass spectra of the unknown analyte with the tandem mass spectra spectra of known compounds inserted in a database. The compounds are usually identified on the basis of spectral match value associated with a probability of recognition. However, this approach is not usually applied to multiple reaction monitoring transition spectra achieved by means of triple quadrupole apparatus, mainly due to the lack of a transition spectra database. The Surface Activated Chemical Ionization‐Electrospray‐NIST Bayesian model database search (SANIST) platform has been recently developed for new potential metabolite biomarker discovery, to confirm their identity and to use them for clinical and diagnostic applications. Here, we present an improved version of the SANIST platform that extends its application to forensic, pharmaceutical, and food analysis studies, where the compound identification rules are strict. The European Union (EU) has set directives for compound identification (EU directive 2002/657/EC). We have applied the SANIST method to identification of 11‐nor‐9‐carboxytetrahydro‐cannabinol in urine samples (an example of a forensic application), circulating levels of the immunosuppressive drug tacrolimus in blood (an example of a pharmaceutical application) and glyphosate in fruit juice (an example of a food analysis application) that meet the EU directive requirements. Copyright © 2016 John Wiley & Sons, Ltd.


  • Generation by mutasynthesis of potential neuroprotectant derivatives of the bipyridyl collismycin A

    by Carlos Sialer, Ignacio García, Javier González-Sabín, Alfredo F. Braña, Carmen Méndez, Francisco Morís, José A. Salas